VANCOUVER, British Columbia–(BUSINESS WIRE)–ARTMS Products, Inc. announced today that it has been invited to
present at the National Nuclear Security Administration’s 2018 Mo-99
Topical Meeting on Tuesday, September 25th and the Third
International Symposium on Technetium and other Radiometals in Chemistry
and Medicine on Thursday, September 27th.
Joel Kumlin will present at the 2018 Mo-99 Topical Meeting in Knoxville,
TN, during Session 7, Production Projects and Technologies II, at
13:00EDT on September 25th.
Mr. Kumlin will be discussing progress on implementation of the ARTMS
QUANTM Irradiation System™ for producing technetium-99m. The QIS™
combines local production control and a cost-effective, easy-to-use
solid target system for the production of Tc-99m on most cyclotron
systems. ARTMS recently announced that the QIS™ received CE mark
approval and has been installed in a number of countries throughout the
ARTMS also announced that Dr. Paul Schaffer, CTO, has been invited to
present at the Third International Symposium on Technetium and other
Radiometals in Chemistry and Medicine in Bressanone, Italy during
Scientific Session C at 15:35CEST on September 27th.
Dr. Schaffer will be discussing advances in QIS™ for producing
high-value radioisotopes, such as Tc-99m, Ga-68, Zr-89 and Cu-64.
About 2018 Mo-99 Topical Meeting
The U.S. Department of Energy’s (DOE) NNSA manages the 2018 Mo-99
Topical Meeting, taking place in Knoxville, Tennessee from September
23-26, 2018. The meeting allows policy and technical experts to present
progress on the production of Mo-99 (Tc-99m) without the use of HEU in
support of non-proliferation objectives and global supply reliability.
About TERACHEM 2018
The Third International Symposium on Technetium and other Radiometals in
Chemistry and Medicine (TERACHEM) will feature invited lectures and
presentations on the development of medically relevant radiometals and
their application in chemistry, radiopharmacy and nuclear medicine.
Based in Vancouver, British Columbia, ARTMS is a leader in the
commercialization of novel technologies and products which enable the
production of the world’s most-used diagnostic imaging isotope,
technetium‐99m (Tc‐99m), using medical cyclotrons. ARTMS holds the
exclusive global commercialization rights to this award-winning and
proprietary Canadian invention which addresses these challenges and
offers the prospect of revolutionizing the nuclear medicine industry.
Dr. Michael Cross